Podcasts about medical science

“Welcome, welcome our wonderful audience!” Dr. Peter Breggin opened The Breggin Hour this week, talking about the effects of his stroke and about our efforts to seek rehabilitation, offering the best chance of optimizing recovery from brain damage. The indomitable Karen Kingston, who has been exposing the dangers of the mRNA vaccines for over five years, joined us. Peter spent a portion of the hour further detailing his experience of receiving treatment at the AVIV clinic, which offers a very specialized program of Hyperbaric Oxygen Treatment (HBOT). Peter made a comment at some point in the program, stating we must “muster great courage equal to our fear…” That phrase sums up for me my husband's attitude since his stroke. He is forging ahead, determined to embrace with both arms the work required to heal. During the third segment, we lost audio with Karen Kingston, so Peter and I finished up discussing artificial intelligence, and Karen's point that AI has been introduced just at a time when the human population is suffering from unprecedented amounts of neurological damage, from the mRNA vaccines as well as from other sources. She pointed out that the creators of the AI programs being used were doing the thinking—the cognitive work—for the individuals using it, which means humans are doing less independent thinking and creating increasing dependency upon outside sources. The neuropsychiatric damage done by mRNA vaccines is being clearly identified. Peter was a coauthor, along with other noted experts, of a recently published scientific paper: “Association Between COVID-19 Vaccination and Neuropsychiatric Conditions,” published in the International Journal of Innovative Research in Medical Science. The paper details over 58 profound neurological adverse effects resulting from mRNA vaccines. Dr. James Thorp spearheaded this research as lead author. The show was a mix of the deeply personal and an examination of some of the threats to humanity's future, with some sweet moments between Peter and Ginger.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

In this conversation, Dr. Iman Farajallah shares her profound experiences and insights as a psychologist working with trauma, particularly in war zones like Gaza. She discusses her personal background, the impact of war trauma on children, and her efforts to give a voice to those affected. The conversation also touches on the challenges of mental health support in Gaza and the concept of complex continuous trauma, highlighting the ongoing struggles faced by the Palestinian population. This conversation delves into the profound and complex trauma experienced by the population of Gaza, particularly focusing on the impact on children. The discussion highlights the continuous nature of trauma, the intergenerational effects, and the parallels with other marginalized communities. Dr. Farajallah shares insights from her work training first responders and supporting refugees, as well as her personal journey of healing through spirituality. Watch on YouTube: https://youtu.be/-ZcfFTPEuro Continuing Education Credits (https://www.cbiconsultants.com/shop) BACB: 1.5 Ethics IBAO:  1.5  Cultural QABA: 1.5  General CBA:    1.5  Cultural Diversity  Follow us! Instagram: https://www.instagram.com/behaviourspeak/ LinkedIn:  https://www.linkedin.com/in/behaviourspeak/ Contact: LinkedIn https://www.linkedin.com/in/dr-iman-farajallah-psyd-6aa190149/ Links: My Life Is a War: Voices of Traumatized Palestinian Children under Israeli Occupation https://a.co/d/cUFdLEA Articles Mentioned: Farajallah, I. (2022). Continuous traumatic stress in Palestine: The psychological effects of the occupation and chronic warfare on Palestinian children. World Social Psychiatry, 4(2), 112-120. Farajallah, I., & Farajallah, H. (2024). Challenges in access to safe drinking water and its impact on maternal and child health in Gaza. Anatolian Clinic the Journal of Medical Sciences, 29(Special Issue on Gaza), 52-65. Farajallah, I. (2024). Behind the Rubble: Psychological trauma of wars and human rights abuses on women and children in Gaza. Anatolian Clinic the Journal of Medical Sciences, 29(Special Issue on Gaza), 119-136. Farajallah, I. (2018). Children of War: Psychological Impacts of War and Postwar Trauma on the Palestinian Children in the Gaza Strip (Doctoral dissertation, Sofia University). Related Behaviour Speak Episodes Episode 239: Supporting Refugee and Migrant Students Amid Climate and War-Induced Displacement with Dr. Diana Diaków https://www.behaviourspeak.com/e/episode-239-supporting-refugee-and-migrant-students-amid-climate-and-war-induced-displacement-with-dr-diana-diakow/ Episode 232: Behaviour Analysis in Sudan with Salma Abdelrahmanabdalla https://www.behaviourspeak.com/e/episode-232-behaviour-analysis-in-sudan-with-salma-abdelrahmanabdalla-med-iba-qba/ Episode 197: Understanding Moral Injury with Dr. C. Richard Spates https://www.behaviourspeak.com/e/episode-197-understanding-moral-injury-with-dr-c-richard-spates/ Episode 191: Behaviour Analysis in Belarus with Анна Калиновская ((Hanna Kalinouskaya), M.A., BCBA, IBA  https://www.behaviourspeak.com/e/behaviouranalysis-in-belaruswith-hannakalinouskaya-bcba-iba/ Episode 184 Behavior Analysis in Ukraine with Alla Moskalets https://www.behaviourspeak.com/e/episode-184-behavior-analysis-in-ukraine-with-alla-moskalets/ Episode 176: Religion, Spirituality, and Mental Health with Dr. Janice Parker https://www.behaviourspeak.com/e/episode-176-religion-spirituality-and-mental-health/ Episode 139: Threads of Hope: Addressing Trauma Amid War and Civil Discord with Sawsan Razzouk, M.A., BCBA https://www.behaviourspeak.com/e/episode-139threads-of-hope-addressing-trauma-amid-war-and-civil-discord-with-sawsan-razzouk-ma-bcba/

For centuries, malaria has been one of the deadliest diseases on the planet. Nearly half of the world remains at risk of malaria with more than half a million deaths each year, most of them in children. While some progress has been made in controlling malaria and developing a vaccine, this has stalled recently, with a growing number of deaths since 2019. At the heart of the challenge is the lack of non-invasive and rapid diagnostic technologies for malaria, which are urgently needed, especially in remote or low-resource areas with limited healthcare infrastructure. Happily, a new frontier in medical technology is offering hope, in the form of the Cytophone, a revolutionary device that can detect malaria through the skin without drawing a single drop of blood. This innovation, developed by a team led by Prof. Vladimir Zharov at the University of Arkansas for Medical Sciences and licensed to Cytoastra for further commercialization, represents a leap forward not just in malaria diagnostics, but in how we might monitor disease altogether.

On today's show, we hear about new research from the University of Arkansas for Medical Sciences that could help explain why the Marshallese community faces higher rates of chronic health conditions. We also learn about the influence of Lucinda Williams' music. Plus, a different kind of Veterans Day celebration in Gentry this weekend.

Obesity is a serious and costly chronic disease that has been widely recognized as a public health epidemic. Although there are accessible, affordable, and straightforward tools to address it in individuals and broader communities, obesity remains a widespread public health threat that increases one's risk for developing other conditions such as heart disease, type 2 diabetes, and some forms of cancer. Trust for America's Health recently published its “State of Obesity 2025” report, which notes that Arkansas has the fifth-highest adult obesity rate in the nation. To learn more about the state of obesity in Arkansas and policy options to address it, we're joined on this episode of the Wonks at Work podcast by Dr. Arlo Kahn, ACHI's medical director and a professor in the Department of Family and Preventive Medicine at the University of Arkansas for Medical Sciences who has dedicated much of the last quarter century to addressing this issue.

With Carsten W Israel, Bethel-Clinic, Bielefeld - Germany, and Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac - Serbia. During this podcast, Carsten Israel and Stefan Simovic will discuss how electrophysiology can adopt sustainable practices while maintaining high-quality patient care. 

For more than half a century, lithium has been one of the most reliable treatments for bipolar disorder. It has given countless people the ability to stabilize their moods and reclaim lives otherwise disrupted by cycles of mania and depression. But lithium comes with inherent risk: its therapeutic range is narrow, which means that the difference between a helpful dose and a harmful one is surprisingly small. Too much lithium in the body can lead to a cascade of health problems, including neurological confusion, tremors, kidney dysfunction, and, though much less well known, potentially dangerous effects on the heart. In a recent publication, Dr. Jeffrey Curran Henson of the University of Arkansas for Medical Sciences, and colleagues, shed light on one of lithium's most alarming but underappreciated risks: its ability to disrupt the heart's natural pacemaker, the sinus node. Their case study and systematic review tell the story of a patient whose life was threatened not by the mental illness she had long managed, but by the very medication that had allowed her to manage it. And in that story, the researchers also describe a novel way out: a treatment that avoided the need for invasive procedures and could reshape how we think about emergency care for lithium-related heart complications.

On Today's episode of Transforming Healthcare with Dr. Wael Barsoum, we have special guests Dr. Jason Sansone and Benjamin Jarvis. Dr. Jason Sansone, MD, is a board-certified, fellowship-trained orthopedic surgeon and the President of Orthopedic & Spine Centers of Wisconsin. He specializes in spine surgery and orthopedic traumatology. A Wisconsin native, Dr. Sansone earned his Doctor of Medicine from the University of Wisconsin School of Medicine and Public Health and completed his orthopedic surgery residency at the University of Wisconsin Hospital and Clinics. He also holds a Bachelor of Science in Medical Sciences from the University of Wisconsin. He is a Fellow of the American Academy of Orthopedic Surgeons (AAOS) and an active member of the Wisconsin Medical Society. Dr. Sansone's specialty fellowship training includes spine surgery, enabling him to provide advanced care for conditions affecting the spine, as well as orthopedic traumatology, which encompasses both operative and non-operative care of complex fractures. Benjamin Jarvis is the Executive Vice President of Wisconsin Operations at Healthcare Outcomes Performance Co. Benjamin previously held various administrative and managerial roles in the healthcare industry, including Administrator of Surgical Operations at SSM Health, Practice Manager at NorthShore University HealthSystem, and Account Manager at Aerotek Scientific. Benjamin holds a Master of Science in Health Systems Management from RUSH University and a Bachelor's degree in Medical Microbiology & Immunology, Biology from the University of Wisconsin-Madison. Join us as we talk about the successes and pitfalls of their journey to starting an orthopedic practice from scratch.

In Episode 2 of this season, we explore the evolution of beauty (especially in birds) and the beauty of innovation, with guest Matt Ridley.Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, Genome, The Rational Optimist, The Evolution of Everything, How Innovation Works, and Viral: the search for the origin of covid-19 (co-authored with Alina Chan). His latest book is Birds, Sex, and Beauty.He served the House of Lords between 2013 and 2021 and served on the science and technology select committee and the artificial intelligence select committee.He was founding chairman of the International Centre for Life in Newcastle. He created the Mind and Matter column in the Wall Street Journal in 2010 and was a columnist for the Times 2013-2018. He is a fellow of the Royal Society of Literature and of the Academy of Medical Sciences, and a foreign honorary member of the American Academy of Arts and Sciences. He lives in Northumberland.In this episode, we talk about:The myth of “disruptive innovation” and the overlooked beauty of incremental progressThe real relationship between basic science and technologyWhy Ridley still calls himself a “rational optimist”Why freedom, not brilliance, is the secret sauce of innovationHow universities and industry can collaborate to keep creativity aliveTo learn more about Matt's work, you can find him at: https://www.mattridley.co.uk/ Books and resources mentioned:Birds, Sex and Beauty (by Matt Ridley) How Innovation Works (by Matt Ridley)The Rational Optimist (by Matt Ridley)The Mating Mind (by Geoffrey Miller)The Descent of Man (by Charles Darwin)The Genetical Theory of Natural Selection (by Ronald Fisher)Survival of the Prettiest: The Science of Beauty (by Nancy Etcoff)The Rational Optimist Society – rationaloptimistsociety.com This season of the podcast is sponsored by Templeton Religion Trust.Support the show

“At some point, feeling good wins over old thoughts.” –VJ HamiltonStruggling with autoimmune disease — or uncomfortable symptoms that you've just learned to live with? What if you could reverse your symptoms? I'm so excited to talk with VJ Hamilton, registered nutritionist and a functional medicine practitioner who specializes in autoimmune disease.I was diagnosed with celiac disease fairly late in life. When I was diagnosed, it just made so much sense and explained so many things. It also led to change. And that can be hard to navigate on your own.Perimenopause and menopause symptoms and those of autoimmune diseases — like brain fog, joint aches, and fatigue — can be signs of both. Plus shifts in hormones can certainly trigger changes or unmask hidden inflammation. Testing and treatment can help.We talk about: Autoimmune disease 101 — what we're actually talking aboutTriggers vs. root causes and how to find the root causeHow to advocate for yourself with doctors and what other practitioner you might want to seeSimple changes you can make to improve your healthFocus not on what you have to cut out for food or what exercise you have to do, but what you need and what you likeEating whole foods instead of prepared meals and how to navigate restaurants and special eventsABOUT VJVJ Hamilton is the founder of The Autoimmunity Nutritionist and an expert in autoimmune disease, specialising in skin disorders, chronic fatigue, joint health, and digestive issues for both men and women.As a Registered Nutritionist with a Medical Science degree (BSc) in Biochemistry & Immunology and having completed the full certification programme at the renowned Institute for Functional Medicine, VJ uses evidence-based nutritional therapies to support her clients in transforming their health.LINKShttps://theautoimmunitynutritionist.com/https://www.instagram.com/theautoimmunitynutritionist/ https://www.linkedin.com/in/theautoimmunitynutritionist/ DOABLE CHANGESAt the end of every episode, we share three doable changes, so you can take what you've heard and put it into action. Action is where change happens. But here's the thing: when we have a goal, a wish, a desire bubbling up in us, it can feel really huge. Sometimes we stop ourselves in our tracks based on how huge our desire feels. Change needs action, but it doesn't need huge action. When we focus on the next step, the next Doable Change that we can integrate into our lives, we don't get stuck and we create momentum. Choose one Doable Change that resonates with you today and really play with it. Fit it into your life, your days, make it work for you — then move on to your next Doable Change. Here are Three Doable Changes from this conversation: MAKE A LIST OF THINGS YOU LOVE TO DO. Changing your lifestyle doesn't have to be terrible! Make a list of things you love to do. Ways you like to be active, rest, connect with others. Make a list of things that make you feel good! Plan for more of those things in your life. That might look like swapping dancing for a gym session or eating food that gives you energy or going to bed on time.RESET IDEAS AROUND FOOD. Here are a few ways to try this Doable Change. First, instead of asking, “What do I have to cut out?” think about what foods you can...

In this week's episode of The Energy Code, Dr. Mike Belkowski returns to the roots of his red-light research—breaking down four powerful new studies that reveal just how multifaceted photobiomodulation truly is.   From boosting mitochondrial function and improving sleep to reducing chronic pain and supporting mental health, Dr. Mike explores the data behind red and near-infrared light and what it means for athletes, biohackers, and anyone pursuing optimal energy and longevity.   Dr. Mike dives into: A systematic review on whole-body red-light therapy for exercise performance and recovery The connection between melatonin production and mitochondria How red light can relieve fibromyalgia pain and calm an over-sensitized nervous system A study showing transcranial near-infrared light can reduce anxiety, depression, and drug cravings The latest FDA-approved findings for age-related macular degeneration   This deep-dive connects the science to real-world strategies—helping listeners understand how to personalize light therapy for maximum mitochondrial, mental, and cellular benefits. Key Topics Covered The myth of “more light equals better results” Why localized red-light therapy outperforms full-body setups for muscle recovery How red light enhances melatonin and circadian alignment for deeper sleep Using red light to calm the nervous system and reduce systemic inflammation New clinical results showing brain-based red light reduces depression and cravings FDA authorization for light therapy in macular degeneration How to calculate your optimal dosage with BioLight's free treatment calculator Key Quotes from Dr. Mike Belkowski   “Your mitochondria are environmental sensors — when they see the wrong light, they know it.” “Localized light on target tissue beats whole-body treatments when it comes to performance.” “Red light therapy can calm an overstimulated nervous system and retrain your pain pathways.” “The more we standardize light protocols, the more consistent and powerful the results will be.” Episode Timeline   00:00 – Morning sunrise + intro 02:30 – What's new in the mitochondrial matrix 07:00 – BioMinerals discount announcement 08:00 – Study #1: Whole-body red light for performance 15:00 – Why dosage and location matter 16:00 – Red light, melatonin & sleep quality 19:00 – Red light's stress-reducing parasympathetic effects 23:00 – Study #2: Fibromyalgia and chronic pain reduction 30:00 – How red light calms sensitized nerves 33:00 – Study #3: Transcranial red light for mood & craving 36:00 – Near-infrared brain protocols explained 37:00 – Study #4: Red light for macular degeneration 44:00 – Why research results can appear contradictory 46:00 – Final thoughts: dosage, nuance, and mitochondrial optimization

EDIT: This episode has been edited after broadcast to accurately reflect the input of the author of the petition to Mandate Trauma-Informed Training for All NSW Police Officers, Claudia Kuper. Over ten thousand people have signed a legislative assembly petition calling for mandated trauma-informed training for NSW Police. Producer Pongyada Sootthipong speaks to lead petitioner Claudia Kuper and solicitor Sam Lee about trauma-informed responses and what systemic reforms are needed to implement them. Cameron Francis, the CEO of not-for-profit drug testing service organisation The Loop joins us to discuss Queensland's recent ban on public and private pill testing operations. We unpack the impacts of keratoconus (a chronic eye condition) on young people with Dr Jingjing You, a senior lecturer at the University of Sydney's School of Medical Sciences. Have raves lost their meaning? Producer Bec Cushway investigates the history of raves and how Sydney's rave scene is being diluted. The National Association of Renters' Organisations and National Shelter have released their second report card on renting in Australia. Producer Sana Shaikh speaks to CEO of the Tenants' Union of NSW Leo Patterson Ross on how New South Wales fared and what the results mean for Sydney renters. This episode of Backchat was produced by Pongyada Sootthipong, Nyaboth Chuol, Elise Papaioannou, Sana Shaikh and Bec Cushway. Executive produced by Bec Cushway. Hosted by Dani Zhang and Bec Cushway. Aired 27 September 2025 on Gadigal land. Want to support our show? Follow us on Spotify and Apple Podcasts, leave us a five-star review, and share an episode with a friend. See omnystudio.com/listener for privacy information. See omnystudio.com/listener for privacy information.

In Episode 2 of this season, we explore the evolution of beauty (especially in birds) and the beauty of innovation, with guest Matt Ridley.Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, Genome, The Rational Optimist and The Evolution of Everything. His book on “How Innovation Works” was published in 2020, and "Viral: the search for the origin of covid-19", co-authored with Alina Chan, was published in 2021.He served the House of Lords between 2013 and 2021 and served on the science and technology select committee and the artificial intelligence select committee.He was founding chairman of the International Centre for Life in Newcastle. He created the Mind and Matter column in the Wall Street Journal in 2010 and was a columnist for the Times 2013-2018. He is a fellow of the Royal Society of Literature and of the Academy of Medical Sciences, and a foreign honorary member of the American Academy of Arts and Sciences.He lives in Northumberland.In this episode, we talk about:How Ridley's childhood fascination with birds led him to study evolutionThe courtship rituals of black grouse and the surprising role of female choiceHow Ronald Fisher's “sexy sons” hypothesis changed everythingWhat bowerbirds can teach us about aesthetics and artSexual selection as a driver of creativity, humor, and the human brainTo learn more about Matt's work, you can find him at: https://www.mattridley.co.uk/ Books and resources mentioned:Birds, Sex and Beauty (by Matt Ridley) How Innovation Works (by Matt Ridley)The Rational Optimist (by Matt Ridley)The Mating Mind (by Geoffrey Miller)The Descent of Man (by Charles Darwin)The Genetical Theory of Natural Selection (by Ronald Fisher)Survival of the Prettiest: The Science of Beauty (by Nancy Etcoff)The Rational Optimist Society – rationaloptimistsociety.com This season of the podcast is sponsored by Templeton Religion Trust.Support the show

Dr. Uri Tabori is a Staff Physician in the Division of Haematology/Oncology, Senior Scientist in the Genetics & Genome Biology program, and Principal Investigator of The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children (SickKids). Uri is also a Professor in Paediatrics and Associate Professor in the Institute of Medical Sciences at the University of Toronto. Uri works as a physician treating kids with cancer, particularly brain tumors. Through his research, he is working to identify drugs and make new discoveries that may cure cancers or improve patients' lives. When he's not hard at work in the lab or clinic, Uri enjoys spending time with his family, watching American football, and exploring the wilderness of Canada. He is especially fond of canoeing and canoe camping with his family. He received his MD from the Hadassah School of Medicine of Hebrew University in Israel. Afterwards, he completed a Rotating Internship and his Residency in Pediatrics at the Sorasky Medical Center in Israel. Next, Uri accepted a Fellowship in Pediatric Hematology and Oncology at the Sheba Medical Center in Israel. He served as a Staff Physician in Pediatric Hematology and Oncology at The Sheba Medical Center for about a year before accepting a Research and Clinical Fellowship at The Hospital for Sick Children in Canada SickKids where he remains today. Over the course of his career, Uri has received numerous awards and honors, including the Early Researcher Award from the Ontario Ministry of Development and Innovation, the New Investigator Award from the Canadian Institute of Health Research, the Junior Physician Research Award from the University of Toronto Department of Pediatrics, The New Investigator Award from the Terry Fox Foundation, A Eureka! new investigator award from the International Course of Translational Medicine, A Merit Award from the American Society of Clinical Oncology Annual Meeting, and The Young Investigator Award from the Canadian Neuro-Oncology Society. In our interview, Uri shares more about his life, science, and clinical care.

After 35 years in medicine, Dr. Joe Jacko has seen it all - and he's ready to tell you what the medical industry doesn't want you to know. In our conversation, he breaks down why patients only get half the information they need, how drug studies use misleading statistics, and why evidence-based medicine has become cookbook medicine driven by insurance profits. But this isn't just criticism, it's empowerment. We discuss Blue Zone residents living to 100 without knowing medical science, why purpose can outweigh poor health markers, and practical strategies for advocating for yourself in medical appointments. Dr. Jacko now runs a comprehensive wellness clinic proving that lifestyle medicine works better than pills for chronic conditions. Key topics: patient empowerment, lifestyle medicine, autoimmune healing, finding integrative doctors, Blue Zones longevity secrets, and why gentle movement beats over-exercising.For the complete show notes, links and transcript visit: inspiredliving.show/214

Fear is one of the earliest emotions to have evolved. Most vertebrates – and possibly some invertebrates – show fear when they are threatened. At its most core, fear keeps us alive, helping us flee from predators or avoid dangerous environments. But why does this process sometimes backfire, leaving us paralysed by otherwise harmless phobias? And why do so many people deliberately seek out fearful situations, from horror movies to parachute jumps, when instinct tells us to do the opposite? Can understanding the biology of fear help us conquer it, or simply make us more vulnerable to its impact?This lecture was recorded by Robin May on the 1st of October 2025 at Bernards Inn Hall, LondonProfessor of Infectious Disease at the University of Birmingham, and (interim) Chief Scientist at the UK Health Security Agency, Robin May was appointed Gresham Professor of Physic in May 2022. Between July 2020 and September 2025 he served as Chief Scientific Adviser at the Food Standards Agency (FSA). Professor May's early training was in Plant Sciences at the University of Oxford, followed by a PhD on mammalian cell biology at University College London and the University of Birmingham. After postdoctoral research on gene silencing at the Hubrecht Laboratory, The Netherlands, he returned to the UK in 2005 to establish a research program on human infectious diseases. He was Director of the Institute of Microbiology and Infection at the University of Birmingham from 2017-2020. Professor May continues his work on Infectious Disease at the University of Birmingham. A Fellow of the Academy of Medical Sciences, Wolfson Royal Society Research Merit Fellow and Fellow of the American Academy of Microbiology, Professor May specialises in research into human infectious diseases, with a particular focus on how pathogens survive and replicate within host organisms.As the FSA's Chief Scientific Adviser, Professor May provides expert scientific advice to the UK government and plays a critical role in helping to understand how scientific developments will shape the work of the FSA, as well as the strategic implications of any possible changes.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/why-fearGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Let's Talk WITH Young Researchers: our podcast sideline in which we give the word to young researchers in the field of women's mental health!In this episode, meet Romina Garcia de leon, PhD researcher at the Institute of Medical Sciences at the University of Toronto and part of the Laboratory of Behavioural Neuroendocrinology at the Centre for Addiction and Mental Health in Toronto, where she works under the supervision of the one-and-only Dr. Liisa Galea.We discuss Romina's preclinical research on the heterogeneity of peripartum depression and the role hormones and immune signaling play - including in treatment. Romina also speaks openly about the challenges of pursuing a PhD, but also about what she loves about it. At the end of the podcast, Romina answers our renowned "3 burning questions": Who is your science crush? What did you not know/expect before starting a PhD? What do you enjoy most about your work as a PhD researcher? Do you want to get in touch with Romina? Reach out to: Romina.Garcia@camh.ca... or find her here:https://www.galealab.com/rominagarciahttps://womenshealthresearchcluster.com/profile/romina-garcia-de-leon/https://www.linkedin.com/in/romina-garcia-de-leon-7b2976149/Sound recording: Franziska WeinmarEditing: Franziska WeinmarDo you have any feedback, suggestions, or questions? Get in touch with us: irtg2804.podcast@gmail.comAre you intrigued by this topic and want to be kept updated? Follow us on twitter: @irtg2804 or instagram: @irtg2804 Hosted on Acast. See acast.com/privacy for more information.

In India the so-called pharmacy of the world children are dying from the very medicines meant to heal them. The Morning Brief’s latest audio deep dive travels from rural Madhya Pradesh to Tamil Nadu’s factories to uncover how a cough syrup laced with industrial chemicals like diethylene glycol killed at least 25 children and how a system built on 80-year-old drug laws allowed it. Host Anirban Chowdhury talks to fathers who lost their children,  Dr Arvind Bagga, professor emeritus and former head of pediatrics at the All India Institute of Medical Sciences, Pramod Verma, Inspector General at Jabalpur, Madhya Pradesh,  public health activist and author Dinesh S Thakur, lawyer and author Prashant Reddy T. Dinesh, JJ Hospital veteran Dr Ishwar Gilada  and ET's pharma editor Vikas Dandekar This story exposes a broken drug regulation system and the human cost of neglect. Tune in: You can follow Anirban Chowdhury on his social media: Twitter and LinkedinYou can follow Dia Rekhi on social media: Linkedin & TwitterListen to Corner Office Conversation our new show:: Corner Office Conversation with Pawan Goenka, Chairman, IN-SPACe, Corner Office Conversation with The New Leaders of Indian Pharma and much more. Check out other interesting episodes from the host like: Why Is India Still Buying Russian Oil?, How AI is Rewriting Cinema Part 2, Trump vs Harvard: India Impact, Of Dragons and Elephants: Modi–Xi in Focus and much more. Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.See omnystudio.com/listener for privacy information.

Bridging Science and Spirit: Mind Wellness & Transformation with Niharika RajnalaHost: Victoria JohnsonGuest: Niharika Rajnala, M.Sc., PhD (Candidate) – Health Science Professional, Certified Heal Your Life® Coach, Mind Wellness & Transformation CoachIn this empowering episode, Victoria Johnson welcomes Niharika Rajnala, a passionate Health Science Professional and Mind Wellness Coach based in Victoria, BC, Canada. With over 13 years of experience spanning mind wellness, clinical research, public health, academic research, and medical writing, Niharika shares how she blends Louise Hay's transformational philosophy with her scientific background to help others heal from the inside out.Niharika Rajnala holds a Master's Degree in Medical Science and is currently pursuing her PhD. She is a Researcher at a leading cancer clinic, contributing to advancements across multiple therapeutic areas:Oncology: Lung Cancer, Cervical Cancer, Breast CancerNeurochemistry: Alzheimer's DiseaseImmunology: PsoriasisInfectious Diseases: Pediatric HIVHer exceptional work has earned her several international awards and recognition in Research & Development and the Pharmaceutical Industry.She offers insights into the connection between science and spirituality, the power of affirmations, and how to create mental and emotional balance through intentional daily practices.“The point of power is in the present moment.” – Louise HayAs a Certified Heal Your Life® Coach, Niharika is passionate about mind wellness, transformation, and emotional healing. Through her YouTube channel, she shares guided meditations, affirmations, and healing practices, inspiring a global audience to live consciously and joyfully.Science Meets Soul: How medical research and Louise Hay's teachings work hand-in-hand to promote holistic healing.Affirmations as Medicine: Using positive thought to reframe stress and enhance mental clarity.Mind Wellness Practices: Simple daily rituals for balance, resilience, and self-love.Global Impact: Bringing healing to people worldwide through digital content and compassionate coaching.Presence and Power: Returning to the moment to access peace, awareness, and possibility.“I bring together medical science and mind wellness to help people transform from the inside out.” – Niharika Rajnala“The point of power is in the present moment.” – Louise Hay“Our minds are powerful allies in healing when guided by love, not fear.” – Niharika RajnalaGround Yourself: Pause and take three slow breaths before your next task. Affirm the Positive: Repeat, “I am healthy, whole, and complete.” Learn & Reflect: Visit Niharika's YouTube channel and explore a guided meditation that speaks to your current season.⁠YouTube⁠⁠LinkedIn ⁠To learn more about Heal Your Life® Coach training with Victoria Johnson PhD, ⁠please visit our website. ⁠

Bridging Science and Spirit: Mind Wellness & Transformation with Niharika RajnalaHost: Victoria JohnsonGuest: Niharika Rajnala, M.Sc., PhD (Candidate) – Health Science Professional, Certified Heal Your Life® Coach, Mind Wellness & Transformation CoachIn this empowering episode, Victoria Johnson welcomes Niharika Rajnala, a passionate Health Science Professional and Mind Wellness Coach based in Victoria, BC, Canada. With over 13 years of experience spanning mind wellness, clinical research, public health, academic research, and medical writing, Niharika shares how she blends Louise Hay's transformational philosophy with her scientific background to help others heal from the inside out.Niharika Rajnala holds a Master's Degree in Medical Science and is currently pursuing her PhD. She is a Researcher at a leading cancer clinic, contributing to advancements across multiple therapeutic areas:Oncology: Lung Cancer, Cervical Cancer, Breast CancerNeurochemistry: Alzheimer's DiseaseImmunology: PsoriasisInfectious Diseases: Pediatric HIVHer exceptional work has earned her several international awards and recognition in Research & Development and the Pharmaceutical Industry.She offers insights into the connection between science and spirituality, the power of affirmations, and how to create mental and emotional balance through intentional daily practices.“The point of power is in the present moment.” – Louise HayAs a Certified Heal Your Life® Coach, Niharika is passionate about mind wellness, transformation, and emotional healing. Through her YouTube channel, she shares guided meditations, affirmations, and healing practices, inspiring a global audience to live consciously and joyfully. Science Meets Soul: How medical research and Louise Hay's teachings work hand-in-hand to promote holistic healing.Affirmations as Medicine: Using positive thought to reframe stress and enhance mental clarity.Mind Wellness Practices: Simple daily rituals for balance, resilience, and self-love.Global Impact: Bringing healing to people worldwide through digital content and compassionate coaching.Presence and Power: Returning to the moment to access peace, awareness, and possibility.“I bring together medical science and mind wellness to help people transform from the inside out.” – Niharika Rajnala“The point of power is in the present moment.” – Louise Hay“Our minds are powerful allies in healing when guided by love, not fear.” – Niharika RajnalaGround Yourself: Pause and take three slow breaths before your next task. Affirm the Positive: Repeat, “I am healthy, whole, and complete.” Learn & Reflect: Visit Niharika's YouTube channel and explore a guided meditation that speaks to your current season.YouTubeLinkedIn To learn more about Heal Your Life® Coach training with Victoria Johnson PhD, please visit our website. If you enjoyed this episode:✅ Subscribe to the Heal Your Life Talk Radio Show

“Toxins are everywhere — in our food, water, and air. They damage our mitochondria, disrupt metabolism, and open the door to disease.” —Dr. Richard ChengIn this episode of the Real Health Podcast, Ron Hunninghake, MD, sits down with Richard Cheng, MD, PhD, ABAARM — physician, researcher, and editor of Orthomolecular Medicine News Service — to explore how environmental toxins and mitochondrial dysfunction are driving today's rise in chronic illness and cancer.Dr. Cheng shares how decades of research have revealed the link between toxins, aging, and cancer and why supporting mitochondrial health and reducing environmental exposure may be one of the most effective preventive strategies in modern medicine.

Listen to JCO Global Oncology's Art of Global Oncology article, "Whispers After the Cure: Reflections on Marriage and Malignancy in India” by Dr. Vangipuram Harshil Sai, who is a fourth semester medical student at All India Institute of Medical Sciences. The article is followed by an interview with Harshil Sai and host Dr. Mikkael Sekeres. Sai shares his personal reflection of a visit which transformed into an education in silence, stigma, and the unseen aftermath of survivorship for young women in India. TRANSCRIPT Narrator: Whispers After the Cure: Reflections on Marriage and Malignancy in India, Vangipuram, Harshil Sai   A Summer Afternoon and A Story That Stayed The summer break of my fourth semester of medical school offered a fleeting reprieve from the relentless immersion in textbooks and caffeine-fueled study sessions. I had envisioned a few weeks of rest—a pause from the algorithms of diagnosis and the grind of multiple-choice questions that had become my daily rhythm. But one humid afternoon altered that plan. I accompanied my mother—a senior medical oncologist—to her clinic in a Tier 2 city in Southern India. Over the years, I had seen her not just as a clinician but as a quiet force of empathy. She was one of those remarkable physicians who listened not just to symptoms but also to stories. Her practice was rooted in presence, and her calm resilience often made my academic anxieties seem trivial. I settled into a corner chair in the waiting area, where the air was tinged with antiseptic and that uncomfortable waiting room stillness—an alert hush between uncertainty and news. Patients waited in quiet constellations: a man turning the same page of a newspaper, a teenage girl watching her intravenous drip as if it held answers, and a couple clasping hands without meeting eyes. It was in this atmosphere of suspended quiet that Aarthi entered. She was a young woman whose presence was composed yet tentative. Her story would become a quiet inflection point in my understanding of medicine. She was 24 years old, embodying the aspirations tied to a recent engagement. A postgraduate in English literature and a practicing psychologist; she carried herself with a rare blend of intellect, poise, and cultural grace that, in the eyes of many families, made her a deeply desirable bride. Her sari was immaculately draped, her posture measured and calm, yet in the way her fingers intertwined and her eyes briefly lowered, there was a trace of vulnerability—a shadow of the turmoil she carried within. She came alone that day, stepping into the waiting room with a composed demeanor that only hinted at the weight she bore in silence. What began as a day to observe became the beginning of something far more enduring: a glimpse into how healing extends beyond treatment—and how survival, though silent, often speaks the loudest. The Diagnosis That Changed the Wedding The consultation was precipitated by a clinical presentation of persistent neck fullness, low-grade fevers, and drenching night sweats, which had prompted a fine-needle aspiration before her visit. The atmosphere in the room held an implicit gravity, suggesting a moment of significant change. My mother, with her characteristic composure, initiated a diagnostic process with a positron emission tomography-computed tomography and biopsy. As usual, her steady presence provided reassurance amid the uncertainty. A week later, the diagnosis of classic Hodgkin lymphoma, stage IIB, was confirmed. Rapid initiation of ABVD chemotherapy would provide an almost certain pathway to remission and an excellent prognosis. Yet, this clinical assurance did not extend to personal tranquility. Aarthi made a deliberate choice to share the diagnosis with her fiancé—a considerate and empathetic individual from a well-regarded family. Their wedding preparations were already underway with gold reserves secured and a vibrant WhatsApp group of 83 members chronicling the countdown to their big day. Shortly thereafter, a prolonged silence settled, eventually broken by a call from a family member—not the fiancé—indicating that the family had decided to terminate the engagement because of apprehensions about future stability. The union dissolved without public discord, leaving Aarthi to navigate the subsequent journey independently. As expected, 6 months of chemotherapy culminated in a clean scan. Her physical health was restored, but an emotional chasm remained, unrecorded by clinical metrics. Yet beneath that silence was a quiet resilience—a strength that carried her through each cycle of treatment with a resolve as steady as any celebrated elsewhere. The regrowth of her hair prompted a conscious decision to trim it shorter, seemingly an assertion of autonomy. Her discourse on the illness shifted to the third person, suggesting a psychological distancing. Her reactions to inquiries about the terminated engagement were guarded. She would yield only a restrained smile, which intimated a multifaceted emotional response. Her remission was certain, yet the world she stepped back into was layered with quiet hurdles—social, cultural, and unseen—barriers far more intricate than the disease itself. Survivorship Without A Map In the weeks that followed Aarthi's diagnosis, I began to notice a quiet but consistent pattern in the oncology clinic—one that extended beyond medical recovery into the unspoken social aftermath. Among young, unmarried women in India, survivorship often came with a parallel challenge of navigating shifts in how they were perceived, particularly as marriage prospects. In Indian families where marital status is closely tied to stability and future security, a woman with a cancer history, even after complete remission, somehow came to be quietly perceived as less suitable. Proposals that had once moved forward with confidence were paused or reconsidered after disclosure. In some cases, financial discussions came with requests for additional support framed as reassurance rather than rejection. These changes were seldom explicit. Yet, across time, they pointed to a deeper uncertainty—about how survivorship fits into the expectations of traditional life scripts. For women like Aarthi, the narrative shifted toward caution. There were subtle inquiries about reproductive potential or disease recurrence and private deliberations over disclosure during matrimonial discussions, even within educated circles. Meanwhile, my observation of the disparity in how survivorship was interpreted across genders in our country left a profound mark on me. A 31-year-old male investment banker who had recovered from testicular cancer was hailed in local media as a testament to fortitude. Male patients seemed to gain social capital from their cancer journeys. This suggested a cultural framework where female value was quietly reassessed, influencing their post-treatment identity through unstated societal perceptions. Digital Ghosting and the New Untouchability Within the digital landscape of curated profiles and algorithmic matchmaking, the reassessment of female survivorship acquired a new dimension. In one instance, a sustained exchange of text messages ended abruptly following the mention of cancer remission. The final message remained unanswered. This form of silent disengagement—subtle, unspoken, and devoid of confrontation—highlighted how virtual spaces can compound post-treatment vulnerability. Designed to foster connection, these platforms sometimes amplified social distance, introducing a modern form of invisibility. Similar to employment status or religion, a cancer history has become another addition to a checklist used to evaluate compatibility. When Medicine Ends, but Society Does Not Begin As a medical student, I felt a growing discomfort. Our curriculum equips us to manage treatment protocols and survival metrics but rarely prepares us for the intangible burdens that persist after cure. What captures the weight of a canceled engagement? What framework supports the quiet reconstruction of identity after remission? Aarthi's path, echoed by many others, revealed a dissonance that medicine alone could not resolve. The challenge was not solely the illness but the reality that she was now unqualified to return to her normal life. Medicine delivers clean scans and structured follow-up, but social reintegration is less defined. In that space between biological recovery and social acceptance, cancer survivors often stand at the edge of wholeness—clinically well but navigating a quieter uncertainty. A Different Ending Two years later, Aarthi's journey took a quiet turn. At a spiritual retreat in Bengaluru, she met an ear, nose, and throat resident who had lost his father to lung cancer. Their connection, shaped by shared experiences, evolved into a partnership grounded in empathy and mutual respect. They married the following year. Their invitation carried a brief but powerful line: “Cancer Survivor. Love Thriver. Come celebrate both.” Today, they comanage a private hospital in Hyderabad. Aarthi leads psycho-oncology services, whereas her partner performs surgeries. He often notes that her presence brings a calm to the clinic that no medication can replicate. Aarthi's journey continues to guide me as I progress through my medical training, reminding me that cure and closure often follow separate paths. Healing, I have come to understand, extends beyond the clinic. It often unfolds in quieter spaces where scans no longer guide us. The real curriculum in oncology lies not only in staging and response rates but in recognizing the many transitions—social, emotional, and cultural—that survivors must navigate long after treatment has concluded. Social stigma is often a second metastasis—undetectable by imaging but present in tone, hesitation, and traditions that quietly redefine survivorship. For many women of marriageable age, treatment marks not the end of struggle but the start of another kind of uncertainty. These survivors carry wounds that do not bleed. Yet, they persist, navigate, and redefine strength on their own terms. Aarthi's quiet resilience became a point of reckoning for me, not as a medical case, but as a guide. Her story is not one of illness alone, but of dignity quietly reclaimed. “Out of suffering have emerged the strongest souls; the most massive characters are seared with scars.”—Khalil Gibran.   Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm professor of medicine and chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. In oncology, we often focus on treatment and a way to find a cure. But what about the expectations and challenges a patient may face from their diagnosis, and even discrimination, especially in different cultures? Today, we're going to examine that space with Harshil Vangipuram, a medical student from India whose JCO Global Oncology article, "Whispers After the Cure: Reflections on Marriage and Malignancy in India," touches on this complexity after treatment. Harshil, thank you for contributing to JCO Global Oncology and for joining us to discuss your article. Harshil Vangipuram: Thank you for having me, Dr. Sekeres. I was raised by a family of oncologists, my mother being a senior medical oncologist and father a senior radiation oncologist. I had exposure to contrasting worlds, which were resource constrained and a cutting edge technology world. And I have unfulfilled curiosity, and I'm still learning, forming ideals. I also see patients as my teachers, so I think that might be helpful. Mikkael Sekeres: Thank you so much for a little bit of that background. So, tell us a little bit about your journey through life so far. Where were you born and where did you do your education? Harshil Vangipuram: I was born in a state called Gujarat in the western part of India. My father got transferred to the southern part of India, so I did my education there. That's it, yeah. Mikkael Sekeres: Okay. That's enough. You're not that old. You haven't had the sort of training and final job that a lot of us have gone through. So, what about your story as a writer? How did you first get interested in writing, and how long have you been writing reflective or narrative pieces? Harshil Vangipuram: I read some books from Indian authors and from foreign, too. And they actually inspired me how patient care was being seen around globally. I always used to carry a hand note. I used to write what I used to see in the clinical postings here at AIIMS. And actually, journaling started as a stress relief for me, and slowly, after hearing patients' stories, it almost became an obligation to write about them. Mikkael Sekeres: Obligation, you use that word, which is such an interesting one. How did writing become an obligation? What did you feel obliged to do when writing about some of the patients you were seeing for the first time? Harshil Vangipuram: Many of them were having struggles which were not seen by everybody. And I got astonished by their confidence and resilience in those situations. So, I thought that I should write about them so that everybody knows about it. And these social stigmas were never talked by anyone around them. So, I felt that if I could voice them, others might eventually know about them. So, that's pretty much the reason I wrote. Mikkael Sekeres: It's so interesting. The people we meet every single day, particularly in hematology oncology, bring such fascinating backgrounds to us, and they're backgrounds that may be unfamiliar to us. And I think that as doctors and writers, we do often feel obliged to tell their stories from the mountaintops, to let other people in on some of the aspects of life and medical care that they're going through and just how inspiring some of these patients can be. Harshil Vangipuram: Yeah, yeah, very true. Very true. Mikkael Sekeres: You mentioned that your mom is a medical oncologist. What kind of influence did she have on your decision to enter medicine and perhaps your own specialty one day? Harshil Vangipuram: Observing my mother practice influenced a lot, and she taught me that medicine is not only about treating a patient, but also listening to their problems. It may be more present in the room. The textbooks I read didn't capture live experiences. I always thought that stories will stay with people longer than actual survival curves. Writing filled that gap between what I studied and what I felt in the OPD. Mikkael Sekeres: It's a great phrase you just whipped out. Patients' stories will stay with us longer than survival curves. Can you tell us a little bit about where her clinic is located? You said in southern India. Can you describe the types of patients she sees? Harshil Vangipuram: It's a small town called Nellore in Andhra Pradesh state. The patients are, most of the time, from a rural population where decisions are mostly family-driven and there's a tight community surveillance and the stigmas are more overt, too. A few of them can be from urban population also, but they have subtler discriminations towards stigmas. Mikkael Sekeres: Can you explain a little further what you mean by decisions are often family-driven? Harshil Vangipuram: If we take marriage, it is often seen as an alliance between two families that are trying to increase their social value, their economic status, and respect in the society. In arranged marriages, for suppose, it's basically driven between these concepts. Mikkael Sekeres: I don't know if it's too personal to ask, but are your parents in an arranged marriage? Harshil Vangipuram: No, not at all. Mikkael Sekeres: So not all the marriages in the clinic are arranged marriages. Harshil Vangipuram: Yeah. Mikkael Sekeres: You know, when you said that decisions are family-driven, you mentioned that people are in arranged marriages. And I wanted to talk a little bit about the stigma you highlight in your essay. I'll talk about that in a second. I thought you were going to go down a route about medical decisions being family-driven, meaning people have to support their families, and getting medical care is costly and takes time away from work, and that sometimes influences decisions about treating cancer. What examples have you seen of that in shadowing your mom? Harshil Vangipuram: I have seen patients who have Hodgkin's lymphoma, breast cancer, and ovarian cancer, who were in the age of 25 to 35, who were getting married. Many of them actually got their engagements broken. And many of them got rejected at matrimonial apps. Many of them also had been told to increase the dowry that is given actually in the form of financial security. Mikkael Sekeres: In your essay, you describe a woman who is engaged and who has a new diagnosis of Hodgkin lymphoma. Can you talk a little bit about the process of getting engaged and marrying in southern India? Harshil Vangipuram: We have the arranged marriage, love marriage, and hybrid, which is kind of arranged and kind of in love. Mostly, these problems really occur in arranged marriages. In love marriages, we don't see that that often because both are understanding about themselves and their families. And both families actually accept them both. Mikkael Sekeres: What's the process of going through an arranged marriage? What happens? Harshil Vangipuram: It can be through parents, relatives, or any known ones or through peers. We just find a man or woman who has a similar caste, who has a good financial income, and people who are respected by the society. And obviously, both the families should have aligned interests for them to accept the marriage. Mikkael Sekeres: About how often are marriages arranged and how often are they love marriages in southern India where you live? Harshil Vangipuram: Almost 90% of the marriages are arranged here. Mikkael Sekeres: Wow. So, your parents were unusual then for having a love marriage. Harshil Vangipuram: Yeah. Mikkael Sekeres: In your essay, you write, and I'm going to quote you now, "Among young, unmarried women in India, survivorship often came with a parallel challenge of navigating shifts in how they were perceived, particularly as marriage prospects. In Indian families where marital status is closely tied to stability and future security, a woman with a cancer history, even after complete remission, somehow came to be quietly perceived as less suitable." Wow, that's a really moving statement. I'm curious, what stories have you seen where, in your words, women became less suitable as a marriage prospect? Harshil Vangipuram: For women, the most important thing in a marriage is, what do you call, a family honor, fertility, and economic status in the community. So, after a long dose of chemo, many people think that people become infertile. In India, basically, we have many misconceptions and stigmas. So, people obviously think that people who have got cancer can spread it to their children or are infertile and are often excluded out of the society as a marriage prospect. Mikkael Sekeres: Gosh, that must be devastating. Harshil Vangipuram: Yeah. Mikkael Sekeres: Does the same occur for men? So, is it also true that if a man has cancer, that he is perceived as less fertile, or it may be perceived that he can pass the cancer on to children? Harshil Vangipuram: Here, after a man beats cancer, they start to celebrate it, like they have achieved something, and it's not like that for a woman. Mikkael Sekeres: In your essay, you do write about a happy ending for one woman. Can you tell us about that? Harshil Vangipuram: Yeah, a cancer survivor obviously met her true love of life in Bengaluru, who was an ENT resident then. And his father died from lung cancer. So obviously, he knew what it felt to beat cancer. Mikkael Sekeres: Yeah, he'd been through it himself. And the irony, of course, is that most cancer treatments that we give do not lead to infertility, so it's a complete misperception. Harshil Vangipuram: Yeah. Mikkael Sekeres: Tell us about your future. What are the next steps for you in your training and what do you hope to specialize in and practice? Harshil Vangipuram: Actually, I'm working on another paper which involves financial toxicity after treatment and post treatment depression. I think it would be completed in another year. And after that, after my med school is completed, I think I'm going to pursue oncology or hematology as my branch of interest. Mikkael Sekeres: Wonderful. It's thrilling to hear that somebody who is as sensitive to his patients and both their medical needs and their needs outside of medicine will be entering our field. It'll be great to know that you'll be taking care of our future patients. Harshil Vangipuram: The pleasure is all mine, sir. Mikkael Sekeres: Harshil Vangipuram, I want to thank you for choosing JCO Cancer Stories: The Art of Oncology and for submitting your great piece, "Whispers After the Cure: Reflections on Marriage and Malignancy in India" to JCO Global Oncology. To our listeners, if you've enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes, follow our show on Apple, Spotify, or wherever you listen, and explore more from ASCO at asco.org/podcasts. Until next time, this has been Mikkael Sekeres from the Sylvester Cancer Center, University of Miami. Have a good day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show notes:Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio:Dr Vangipuram Harshil Sai is a fourth semester medical student at All India Institute of Medical Sciences. Additional Reading Impact of Gender of the Child on Health Care–Seeking Behavior of Caregivers of Childhood Patients With Cancer: A Mixed-Methods Study | JCO Global Oncology

The most important ingredient in cancer treatment is the treatment itself, of course. However, community support groups play a growing role in recovery, for patients, their families, and their caregivers alike. Find a group in your area at https://prostaid.org/meetings/ Prostaid Calgary City: Calgary Address: 1600 90 Avenue Southwest Website: https://prostaid.org/

Karolina Kopyonkina is joined the Active Girls Healthy Women team as the Program Coordinator in June 2025.   Originally from Ukraine, Karolina moved to Kentucky at the start of high school and earned both her Master of Science in Medical Sciences and her Bachelor's in Neuroscience from the University of Kentucky. With experience in health research, teaching, and mentoring, she's passionate about empowering girls to stay active and build confidence.   Karolina is a competitive figure skater who took up the sport as an adult, fulfilling a longtime dream. Now she trains regularly, competes, and performs in recitals at the local ice rink, using her journey as a reminder that it's never too late to try something new or pursue a passion.  If you enjoy this podcast, please click "subscribe" wherever you listen to episodes and we hope you'll consider leaving us a review.  Follow us on Facebook https://www.facebook.com/UKAGHW, Instagram https://www.instagram.com/ukaghw, or LinkedIn https://www.linkedin.com/company/active-girls-healthy-women.   Sign up for the Active Girls Healthy Women newsletter here: http://eepurl.com/h6e30b or learn more about our Program here: https://linktr.ee/ukaghw.  If you want to help us sustain the Champions of Active Women podcast, please consider donating to the University of Kentucky Active Girls Healthy Women Program at https://give.uky.edu/campaigns/47165/donations/new?aft=87003cbf2438ea9d126a47dbe0395353 

With Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia, Augusto Meretta, Leiden University Medical Center, Leiden - The Netherlands, and Jose Luis Merino, La Paz University Hospital, Madrid - Spain. During this podcast, Jose Luis Merino, Stefan Simovic and Augusto Meretta will discuss key insights and innovations behind the 2025 EHRA practical compendium on antiarrhythmic drugs, including its new classification system, clinical guidance across Europe, drug interactions, combination therapies, and the future of pharmacological rhythm control.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover Jimmy Kimmel's controversial return to television, a Supreme Court ruling that could reshape presidential power, the growing struggles of America's farmers and truckers, and new White House warnings about Tylenol and autism. From free speech fights to medical debates, today's brief connects culture, politics, and science shaping America's future.   Jimmy Kimmel Returns to Air with FCC Debate: Disney announced Kimmel would return, calling his remarks “ill-timed and insensitive” but not admitting his claims about Charlie Kirk's assassin were lies. Sinclair caved after death threats, canceling a Kirk tribute and airing Kimmel again. Senators Rand Paul and Ted Cruz blasted Trump's FCC for even raising news distortion, with Cruz comparing it to “Goodfellas.” Bryan warned, “We cannot sit down with the modern Democrat party… they assassinate people who get in the way — like Charlie Kirk.”   Supreme Court Expands Presidential Power: In a 6–3 decision, the Court allowed Trump to fire a Democrat FTC commissioner while hearing the full case in December. The ruling challenges the 1935 precedent limiting executive power. Bryan explains it could restore Jefferson-style authority, including presidential impoundment of spending. “Welcome to the new version of American democracy… it's a bit of a mess right now.”   Farmers, Ranchers, and Truckers Under Pressure: New screwworm cases in northern Mexico threaten U.S. cattle herds already at historic lows. Soybean farmers face collapse as Xi stops buying American crops, while truckers lose money under depressed rates and costly California regulations. Bryan calls for revoking visas of foreign drivers who “can't read or speak English and are killing people on the road.”   White House Links Tylenol to Autism: Trump's HHS and FDA advised pregnant women to limit acetaminophen after new studies showed it can cross the placenta, cause oxidative stress, and disrupt brain development. Critics called the claims weak, but Bryan compared it to past medical dogmas debunked by Dr. Barry Marshall, who proved ulcers were caused by bacteria: “Quite literally the entire world of Medical Science was wrong. That one doctor was right.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Jimmy Kimmel FCC news distortion, Rand Paul Ted Cruz Goodfellas FCC quote, Sinclair cancels Charlie Kirk tribute, Supreme Court Trump FTC ruling, presidential impoundment Jefferson precedent, U.S. screwworm outbreak Nuevo Leon, U.S. soybean farmers China ban, trucker wages California EV mandate, Trump revoke foreign trucker visas, Trump HHS FDA Tylenol autism warning, acetaminophen oxidative stress fetus, Dr. Barry Marshall ulcer Nobel Prize

"Jung was essentially an evolutionary theorist". These are the words of Gary Clark, a Visiting Research Fellow in the School of Medical Sciences at the University of Adelaide in Australia, who has written a book on the intersection of Jungian Analytical Psychology and evolutionary neuroscience. If you want to learn more about Gary you can check out his book "Carl Jung and the Evolutionary Sciences: A New Vision for Analytical Psychology" (and grab a free PDF of its intro) here. You can also dive into the rest of his work on academia.edu and ResearchGate. In this conversation, I sit down with Gary to explore the intersection of Jungian psychology and evolutionary neuroscience, examining how recent psychedelic research provides empirical validation for Jung's theories about the collective unconscious and archetypes. We discuss how modern neuroscience, particularly studies of primary and secondary consciousness systems, maps onto Jung's framework of ego consciousness versus deeper archetypal layers. The conversation covers the revolutionary potential of psychedelic research for studying previously inaccessible aspects of consciousness and Jung's prescient evolutionary approach to depth psychology.⏳Timestamps00:00 James's Intro01:07 Opening and situating Gary's work03:35 Affective Neuroscience and the Primary and Secondary layers of consciousness09:00 Psychedelics, the numinous and evolutionary theory22:17 Have we found the (neuroscientific) archetypes?28:40 Psychedelics and the Collective Unconscious34:53 Jordan Peterson's Jungian synthesis36:57 Peterson gets chimpanzees and ancient humans wrong46:01 Leaving Jung behind: Depth Psychology maturation as a science58:50 Mapovers between Iain McGilchrist's work and Gary's1:01:19 What Gary's working on now1:07:32 Gary's guest recommendation: Erik Goodwyn

In this episode of the ACRO Podcast CURiE Conversations edition, Dr. Jenna Kahn speaks with authors Dr. Scott Silva and med student Caitlin Reichard about their published article, "Dosimetry, Toxicity, and Outcomes of Medically Inoperable Endometrial Cancer Treated With Definitive External Beam Radiation Therapy and Brachytherapy." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article here: https://www.cureus.com/articles/366834-dosimetry-toxicity-and-outcomes-of-medically-inoperable-endometrial-cancer-treated-with-definitive-external-beam-radiation-therapy-and-brachytherapy#!/

Listen to the episode The Role of Nutrition in Managing Chronic Illness hosted by patient advocate Abbie Cornett. In this episode, we'll be exploring how what we eat can directly impact our immune system, energy levels and even our treatment outcomes. Our guest today, Dr. Terry Harville, is a medical director of the Special Immunology Laboratory at the University of Arkansas for Medical Sciences, a consultant for immunodeficiencies, autoimmunities and transplantation and a long-time advocate for holistic whole-person care.  Support the show

In this episode, I dive into the complexities of autoimmunity and the gut-brain axis with Dr. Datis Kharrazian, one of the leading voices in functional medicine. What strikes me about our conversation is how he connects the dots between environment, genetics, and lifestyle, painting a clear picture of why autoimmune diseases are on the rise and why they're so difficult to treat. Dr. Kharrazian breaks down how and why the immune system malfunctions, and more importantly, how lifestyle adaptations can play a pivotal role in managing these conditions. Together, we explore the principles of functional medicine and how they reshape chronic disease care, while also looking at the latest insights into the gut microbiome, its impact on brain health, and the links to conditions like Alzheimer's and long COVID. This episode is packed with professional insights, practical takeaways, and a vision of how functional medicine can transform patient care in today's world. Key Takeaways: Autoimmunity occurs when the immune system mistakenly attacks the body's own tissues, with factors such as environmental exposure and genetic susceptibility being key contributors. Functional medicine prioritizes enhancing bodily functions rather than simply inhibiting disease symptoms, offering a promising approach for managing chronic diseases. Lifestyle factors like sleep, stress management, and exercise play a crucial role in managing autoimmune conditions and maintaining overall health. The gut-brain axis is integral to understanding and treating neurological conditions, with bidirectional communication between these systems influencing health outcomes. Precision diagnostics and individualized care models are essential for effective functional medicine practice, emphasizing the need for education in the field. Dr. Datis Kharrazian is a clinical research scientist, academic professor, and a functional medicine healthcare provider. He is an Associate Clinical Professor at Loma Linda University School of Medicine. Dr. Kharrazian earned a PhD in Health Science with concentrations in immunology and toxicology, and a Doctor of Health Science degree from Nova Southeastern University. He also holds a Master of Science degree in Human Nutrition from the University of Bridgeport, a Doctor of Chiropractic degree from Southern California University of Health Sciences, and a Master of Medical Sciences degree in Clinical Investigation from Harvard Medical School. Dr. Kharrazian completed his post-doctoral research training at Harvard Medical School and Massachusetts General Hospital. He was a researcher at Harvard Medical School for seven years. Currently, he serves as the academic director of the Kharrazian Institute and the Academy of Functional Nutrition and Lifestyle Medicine. Website The Academy of Functional Nutrition and Lifestyle Medicine Instagram Connect with me! Website Instagram Facebook YouTube

Meet Christina Boylston—a Functional Diagnostic Nutrition Practitioner with a Master's in Medical Sciences and over a decade of experience in preventative and regenerative medicine. From battling undiagnosed Hashimoto's and postpartum complications to regaining her energy through functional lab testing, this conversation dives deep into the root causes of exhaustion and burnout for moms.   Want to watch this episode on YouTube? Click here. Subscribe if you'd like to catch all new episodes live and participate with our guests directly.   Want to learn more about becoming an FDN? Go to fdntraining.com/resources to get our best free workshops and mini-courses! Where to find Christina Boylston: Website: layerstowellness.com Instagram: @christina_boylston Facebook: @christina.boylston  

What if hair loss was really a signal from your body, not just a cosmetic issue?In this episode, I talk with VJ Hamilton, The Autoimmune Nutritionist, about overcoming alopecia areata and other forms of hair loss by addressing root causes. We dive into nutrient deficiencies, gut health, thyroid imbalances, and inflammation and how functional medicine can help hair grow back naturally.If you've been told there's no hope for hair loss, this episode will challenge that belief.Episode Timeline: 00:00 – Episode Preview02:07 – Podcast Intro02:32 – Meet VJ Hamilton, Autoimmune Nutritionist04:02 – VJ's Story: Alopecia at Age 705:24 – Reversing Fatigue, Psoriasis, and Chronic Issues08:55 – Hair Loss: Autoimmune vs. Other Causes12:58 – Hair Regrowth: Healing Timeline16:09 – Inflammation Triggers: Gut, Scalp, Whole Body18:12 – Five Key Hair Loss Markers25:44 – Biotin: Overrated or Essential?27:50 – Nutrients: Selenium, Vitamin A, Genetics31:29 – Low Stomach Acid and Absorption33:01 – Supplements vs. Food for Hair Growth35:05 – First Steps with Hair Loss Diagnosis36:07 – Complex Cases: Mold, Toxins, Nervous System39:25 – Connect with VJ Hamilton Online40:42 – Podcast Outro41:03 – Root Cause Healing: Final TakeawaysAbout VJ Hamilton:VJ Hamilton, also known as The Autoimmunity Nutritionist, is the founder of The Autoimmune Nutrition Clinic and a Registered Nutritionist specialising in reversing hair loss, particularly alopecia areata, and other autoimmune-related conditions. With a Medical Science degree (BSc) in Biochemistry & Immunology and certification from the Institute for Functional Medicine, VJ combines scientific expertise with lived experience to deliver evidence-based, personalised therapies. Connect with VJ Hamilton:VJ Hamilton's Website: https://theautoimmunitynutritionist.com VJ Hamilton's FB Page: https://www.facebook.com/A.Nutritionist/ To take the Save My Thyroid Quiz visit www.savemythyroid.com/quiz Free resources for your thyroid health Get your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.com High-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' sHave you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Click Here to access hundreds of free articles and blog posts. Click Here for Dr. Eric's YouTube channel Click Here to join Dr. Eric's Graves' disease and Hashimoto's group Click Here to take the Thyroid Saving Score Quiz Click Here to get all of Dr. Eric's published booksC...

Erika Barber sits down with Erika McCarthy, physician assistant and professor, to explore one of the most pressing questions in healthcare today: Faith vs. Science — can they truly coexist in medicine?This conversation is for anyone curious about the intersection of faith, ethics, and modern medicine: How does grief shape the way medical providers care for patients? What role does hope play in healing? Should spiritual perspectives influence medical education and clinical practice? And what does it look like for healthcare providers to care for the whole person — mind, body, and spirit?Together, they share personal stories of loss, moments of hope, and the ways their Christian faith continues to shape their approach to medicine, education, and patient care.Erika McCarthy is an Assistant Professor of Medical Science at George Fox University. Dr. Erika Barber teaches in George Fox University's physician assistant program and holds board certification in internal medicine and geriatrics.

With Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia, Vera Maslova, University Medical Center of Schleswig-Holstein, Kiel - Germany, Daniel Scherr Medical University of Graz, Austria, and Michal Farkowski, Ministry of Interior and Administration National Medical Institute, Warsaw, Poland. During this podcast Daniel Scherr, Michal Farkowski, Stefan Simovic and Vera Maslova will explore the newly published 2025 ESC-EHRA Atlas on Heart Rhythm Disorders, featured in EP Europace journal offering key insights into global arrhythmia care. 

In this episode of the ACRO Podcast CURiE Conversations edition, Dr. Jessica Schuster speaks with author Dr. Leslie Chang about her published article, "Advancing Professionalism Through a Patient Safety and Quality Improvement Workshop in Radiation Oncology." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article here: https://www.cureus.com/articles/372473-advancing-professionalism-through-a-patient-safety-and-quality-improvement-workshop-in-radiation-oncology#!/

In this episode, Mason sits down with Dr. Carol Haddad to explore a topic close to the hearts of so many—how traditional medical treatments and complementary approaches can work together for deeper healing. Instead of choosing one path over the other, Dr. Carol shares how integration creates a more personalized, compassionate, and effective journey toward wellness. You'll hear real-world examples, practical strategies, and encouraging insights that remind us healing isn't just about treating the body—it's about nurturing the whole person: mind, body, and spirit. Whether you're a patient, caregiver, or simply curious about integrative approaches, this conversation offers hope, wisdom, and a refreshing perspective on what's possible when different worlds of medicine come together. By the end of this episode, you'll feel empowered with new ways to think about health, inspired by stories of resilience, and encouraged to see healing as more than a diagnosis—it's a journey.   Key Insights & Timestamps 02:15 The importance of blending science with holistic approaches 05:42 Why patients shouldn't feel forced to choose “either/or” in treatment 09:10 Dr. Carol's story of how she embraced integrative care 14:27 The role of nutrition and lifestyle in healing 18:55 How mindset and emotional health impact physical recovery 23:40 The science behind complementary therapies 28:05 Stories of patients who found strength through integrative care 33:12 How caregivers can support the journey with compassion 38:46 The future of medicine: collaboration over competition 42:19 Practical steps to begin your own integrative path About Dr. Carol Haddad Dr. Carol is a highly trained physician who bridges the gap between conventional oncology and holistic healing. With a background that includes a Medical Science degree from UNSW, a postgraduate degree in Medicine from the University of Sydney, specialty training in Radiation Oncology, and certification in Functional Medicine, she has more than a decade of experience treating patients within hospital and cancer center settings. Her journey led her beyond traditional medicine into the world of integrative oncology, where she combines evidence-based treatments with complementary therapies such as natural medicine, psycho-energetic healing, nutrition, and lifestyle interventions. This unique approach allows her to deliver truly holistic cancer care—addressing not just the disease, but the whole person. Dr. Carol believes that patients deserve a more balanced model of treatment, one that draws from the strengths of both science and spirituality to improve outcomes and quality of life. Today, she consults with patients and healthcare professionals worldwide, offering guidance on functional medicine, integrative cancer strategies, and ways to minimise side effects while maximising recovery. Her mission is to empower individuals to embrace long-term wellbeing, reduce recurrence risk, and experience healing in a more sustainable way. If you're curious about functional medicine, holistic oncology, or integrative cancer support, this episode is for you.   Resources Mentioned: Email: drcarolhaddad@gmail.com Website: www.drcarolhaddad.com

A new statewide program is aiming to improve maternal and infant health in Arkansas, one of the states with the highest maternal and infant mortality rates in the country.The University of Arkansas for Medical Sciences has launched a three-tiered initiative through its new program, Arkansas Center for Women & Infants' Health. It offers vital resources to new mothers and babies during the critical postpartum period.  Learn more about Nirvana Manning, MD 

In this episode, Dipu Patel, DMSc, MPAS, PA-C, president of the PA Education Association, talks with Brenda Diaz, DMSc, PA-C, program director at Tarleton State University, and Jason Radke, MMS, PA-C, program director at Rosalind Franklin University, about the unique challenges and rewards of leading PA programs. Dr. Diaz, whose 35-year career has centered on rural health and migrant farm workers, and Radke, with experience in pediatrics and emergency medicine, share candid reflections on mentorship, balance, and the personal passions that sustain them. Together, they explore how program directors can be better supported and highlight PAEA's role in strengthening leadership across the profession. This episode is sponsored by Lincoln Memorial University School of Medical Sciences. For more information about the doctor of medical science program, visit https://www.lmunet.edu/school-of-medical-sciences/dms/. For more information on the medical education major curriculum, visit https://www.lmunet.edu/school-of-medical-sciences/dms/medical-education-major-curriculum.   All Things PA Education is produced by Association Briefings.

Filling in for Melissa, host Paul Pacelli chatted with Dr. Traci Marquis-Eydman, Associate Professor of Medical Sciences and Director of the Medical Student Home (MeSH) Program at the Frank H. Netter MD School of Medicine at Quinnipiac University, about recent news that Connecticut Third District Congresswoman Rose DeLauro underwent a procedure to treat a case of spinal stenosis. Image Credit: Getty Images

Join host Kate Boyle on the Mind Movement Health Podcast as she welcomes VJ Hamilton, the founder of the Autoimmunity Nutritionist. VJ shares her personal and professional journey through autoimmune disease, focusing on skin disorders, chronic fatigue, joint health, and digestive issues. As a registered nutritionist with expertise in biochemistry and immunology, VJ provides valuable insights into how simple lifestyle and diet changes can transform health, protect against autoimmune conditions, and improve quality of life. Enjoy this informative discussion aimed at empowering listeners to take control of their well-being.   Connect with VJ Hamilton:   VJ Hamilton is the founder of The Autoimmunity Nutritionist and a leading expert in autoimmune disease, specialising in skin disorders, chronic fatigue, joint health, and digestive issues for both men and women. As a Registered Nutritionist with a Medical Science degree (BSc) in Biochemistry & Immunology and having completed the full certification programme at the renowned Institute for Functional Medicine, VJ uses evidence-based nutritional therapies to support her clients in transforming their health. After overcoming her own struggles with multiple autoimmune conditions, including alopecia areata, psoriasis, and post-viral chronic fatigue syndrome, VJ has been symptom-free for over nine years. She now empowers others through her signature program, The Inflammation RESET®, which helps clients take a personalised approach to managing autoimmune disease and empowers them to take control of their health. VJ also hosts the highly regarded podcast The Autoimmune Reset, where she provides expert insights into managing autoimmune diseases. Through the podcast, listeners gain practical advice and strategies to improve their health and well-being. VJ has also developed a popular 12-part series called Nutrition Essentials, offering valuable information on maintaining health through nutrition.   Email:victoria@theautoimmunitynutritionist.com Website:https://theautoimmunitynutritionist.com/ Podcast:https://podcasts.apple.com/gb/podcast/the-autoimmune-reset/id1646389917 YouTube:https://www.youtube.com/@theautoimmunitynutritionist Instagram:https://www.instagram.com/theautoimmunitynutritionist/ Facebook page:https://www.facebook.com/theautoimmunitynutritionist/ LinkedIn:https://www.linkedin.com/in/theautoimmunitynutritionist/ The Autoimmune Forum (Facebook group):https://www.facebook.com/groups/theautoimmuneforum VJ's signature program, The Inflammation RESET®program:https://vjhamilton.kartra.com/page/THEINFLAMMATIONRESET FREE guide, The Autoimmunity Recovery Plan:https://vjhamilton.kartra.com/page/TheAutoimmunityRecoveryPlan     Connect with Kate: Website: MindMovementHealth.com.au Facebook: facebook.com/MindMovementHealth Instagram: instagram.com/MindMovementHealth Haven't subscribed to the podcast yet? Be sure to subscribe and leave us a review at: Apple Podcasts

The More Sibyl Podcast Presents: 학문의 전설| The Incredible Journey of an Academic Medicine Legend — The One With Professor Onatolu Odukoya | Episode 25 (2025)Legacy. Leadership. Life Lessons. This episode on The More Sibyl Podcast is surely unforgettable. I had the privilege of sitting down with Professor Onatolu Odukoya, the former Chief Medical Director of Lagos University Teaching Hospital.What began as a conversation about legacy evolved into an enriching dialogue about purpose, faith, leadership, and the wisdom that comes with age. We explored his remarkable academic career, starting with his early days as a standout scholar who would later make his mark at Harvard. We discussed the evolution of Nigeria's medical education system, particularly in light of emerging technologies like AI and their impact on diagnostics. Professor Odukoya expressed cautious optimism about the future, hopeful that, with the right reforms and vision, both medical education and the broader healthcare sector in Nigeria can grow and thrive.Now in retirement, Professor Odukoya is far from idle. He continues to serve on several medical and community boards, including the Holy Trinity Hospital Board and the Academy of Medical Sciences. He shared candidly about the fears many high achievers have around retirement, especially the fear of becoming irrelevant, but offered a powerful model for staying engaged and purposeful through service, planning, and faith.We also discussed his newly released memoir, which chronicles his life of discipline, faith, loss, and service. It's not just a story of accomplishments, but of values: how he and his wife have deliberately passed down faith and integrity to their children and grandchildren.This episode is a rich blend of wisdom, history, and practical advice. Whether you're an academic, a parent, a leader, or someone reflecting on your own legacy, Professor Odukoya's story will leave you both challenged and inspired.Oh—and something BIG is coming this month. Mark your calendars for July 19th: More Than a Backpack is a live panel session featuring moms, dads, and a behavioral specialist, who will dig even deeper into how we can collectively advocate for our kids in the North American education system. That's right, both the U.S. and Canada. Save the date, and we'll see you there.

Nutritionist Leyla Muedin discusses the benefits of drinking water over diet beverages for women with type 2 diabetes, highlighting a study that found water consumption led to greater weight loss and a higher rate of diabetes remission. Additionally, the episode explores how a low FODMAP diet can alleviate gastrointestinal symptoms for women suffering from endometriosis. Leyla explains the science behind FODMAPs and provides practical dietary advice for those affected by these conditions.

In today's episode, we had the opportunity to speak with Arndt Vogel, MD, about the European Commission's (EC's) July 2025 marketing authorization of zanidatamab-hrii (Ziihera) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer. Dr Vogel is a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre in Canada. In our exclusive interview, Dr Vogel highlighted the clinical importance of this decision, emphasizing that it represents a significant advancement for a molecularly defined subgroup of patients with limited treatment options and historically poor outcomes. He explained that biliary tract cancers, including cholangiocarcinoma, are associated with high recurrence rates and poor survival, even in patients who undergo curative-intent surgery. For patients in the advanced setting, second-line chemotherapy offers modest clinical benefit, with objective response rates of approximately 6%, a median progression-free survival of approximately 3 months, and a median overall survival of approximately 12 months. Vogel discussed the data supporting the EC's approval, which was based on findings from the phase 2b HERIZON-BTC-01 trial (NCT04466891)—the largest study conducted to date evaluating HER2-directed therapy in this patient population. In the trial, at a median follow-up of 21.9 months, patients with centrally confirmed HER2-positive tumors (n = 80) who received zanidatamab achieved a confirmed objective response rate (cORR) of 41.3% (95% CI, 30.4-52.8). The median duration of response was 14.9 months (95% CI, 7.4-not reached), and the median overall survival reached 15.5 months (95% CI, 10.4-18.5).

About VJ Hamilton: VJ Hamilton is the founder of The Autoimmunity Nutritionist and an expert in autoimmune disease, specializing in skin disorders, chronic fatigue, joint health, and digestive issues for both men and women. As a Registered Nutritionist with a Medical Science degree (BSc) in Biochemistry & Immunology and having completed the full certification program at the renowned Institute for Functional Medicine, VJ uses evidence-based nutritional therapies to support her clients in transforming their health.   What We Discuss In This Episode: Lynne Wadsworth and VJ Hamilton engaged in a discussion about health issues related to midlife, focusing on skin and hair health during menopause, as well as autoimmune disorders. Lynne shared her personal experiences with alopecia and migraines, linking her health challenges to her environment in Florida, while VJ highlighted the connection between skin health and the immune system, emphasizing the impact of diet and climate. VJ recommended dietary changes, such as incorporating omega-3-rich fish and antioxidant-rich foods to reduce inflammation and stressed the importance of high-quality food sources. VJ also explained gut health's role in autoimmune conditions, and how gut bacteria imbalances can lead to inflammation and digestive issues. She advised including a variety of plant-based foods and fiber in the diet, particularly for those on restrictive diets, and encouraged manageable dietary changes.   We discussed health challenges faced during midlife, particularly focusing on skin issues and autoimmune conditions.  VJ recounted her experiences with autoimmune diseases and how they motivated her to pursue a career in nutrition. She highlighted the significance of anti-inflammatory foods, particularly omega-3-rich fish, in managing symptoms and maintaining overall health during midlife. Health and Nutrition Insights - VJ explained that gut health is central to managing autoimmune conditions and overall health, as it affects nutrient absorption and immune response. She noted that an imbalance in gut bacteria can lead to inflammation and digestive issues. Stress management and dietary choices, such as incorporating short-chain fatty acids and a variety of plant-based foods, are essential for maintaining gut health. VJ also mentioned the significance of fiber for gut health and highlighted the need for conscious dietary choices, especially for those on low starch or low grain diets.  She recommended starting with small lifestyle changes that bring joy and suggested focusing on one nutritional improvement at a time, such as cooking whole food instead of relying on ready meals.   Free Resource From VJ Hamilton: The Autoimmune Recovery Plan: https://vjhamilton.kartra.com/page/TheAutoimmunityRecoveryPlan   Connect With VJ Hamilton: Website: https://theautoimmunitynutritionist.com/ Instagram: https://www.instagram.com/theautoimmunitynutritionist Facebook: https://www.facebook.com/theautoimmunitynutritionist LinkedIn: https://www.linkedin.com/in/theautoimmunitynutritionist/ Podcast: https://podcasts.apple.com/us/podcast/the-autoimmune-reset/id1646389917   Connect with Lynne: If you're looking for a community of like-minded women on a journey - just like you are - to improved health and wellness, overall balance, and increased confidence, check out Lynne's private community in The Energized Healthy Women's Club. It's a supportive and collaborative community where the women in this group share tips and solutions for a healthy and holistic lifestyle. (Discussions include things like weight management, eliminating belly bloat, balancing hormones, wrangling sugar gremlins,  overcoming fatigue, recipes, strategies, perimenopause & menopause, and much more ... so women can feel energized, healthy, and lighter, with a new sense of purpose. Website:  https://holistic-healthandwellness.com Facebook: https://www.facebook.com/holistichealthandwellnessllc The Energized Healthy Women's Club:  https://www.facebook.com/groups/energized.healthy.women Instagram: https://www.instagram.com/lynnewadsworth LinkedIn:  https://www.linkedin.com/in/lynnewadsworth   Free Resources from Lynne Wadsworth: ✨ Ready to Thrive in Midlife? Let's Make It Happen!

A few weeks ago we mentioned that the Navy provides pilots with human performance resources, but it turns out we were wrong! A common complaint in that community is "I've been told my entire career that I'm an athlete, but I haven't been treated like one." Our guest this week is a Sports Medicine MD who is working on several initiatives to bring human performance resources to the fleet.We'll forgive him for his past affiliation with Navy football. Commander Kevin Bernstein, MD, MMS, CAQSM, FAAFP is currently Director of Sports and Performance Medicine for Naval Special Warfare Group TWO in Virginia Beach, VA. He is also Chairman of the Human Performance Sub-Community for Navy Medicine's Neuro-Musculoskeletal Readiness Community and Specialty Leader for Navy Primary Care Sports Medicine. He is an Associate Professor of Family Medicine at Uniformed Services University of the Health Sciences.He received his Bachelor of Science in pre-medicine with minors in biology and Jewish studies from the Pennsylvania State University, and his Master of Medical Science and Medical Degree from Drexel University College of Medicine. He completed residency training at Naval Hospital Pensacola where he served as Chief Resident, and fellowship training in Sports Medicine at Naval Hospital Camp Pendleton.After residency, he reported to Fleet Surgical Team SEVEN forward-deployed 24 months as staff Family Physician on 5 patrols augmenting medical support aboard 3 large deck amphibious platforms (LHA 5, LHD 6, LCC-19) in support of amphibious and expeditionary exercises in 7th Fleet.He then reported to Naval Health Clinic Annapolis, serving as Team Physician for 10 NCAA D1 teams including Navy football, Director for Public Health, Chair of the Medical Executive Committee, and Sports Medicine faculty for 5 GME residency programs and USUHS medical students.

Dr. Eduardo Cardona-Sanclemente, integrative medicine doctor with a focus on Ayurveda, has joined me (again) to share his brilliant insights. Please join us as we discuss: the inspiration behind his book: Ayurveda for Obesity and Gut Health his insights on the body/mind connection his philosophies on being grounded to nature an understanding of fat cells and so much more! Welcome to The Healing Place Podcast! I am your host, Teri Wellbrock. You can listen in on Pandora, Apple Podcasts, Spotify, iHeartRadio, Deezer, Amazon Music, and more, or directly on my website at www.teriwellbrock.com/podcasts/. You can also catch our insightful interview on YouTube. Bio: Dr. Eduardo Cardona-Sanclemente Dr. Eduardo Cardona-Sanclemente's medical and scientific career spans professorships and senior scientific research posts at a number of Europe's most distinguished medical schools and universities including The William Harvey Research Institute (WHRI, London); St. Bartholomew's Hospital Medical College (London); King's College London; Institut Pasteur (Paris); Salpêtrière Hospital (Paris); Institut Biomedical des Cordeliers (Paris); Sorbonne University (Paris) and the University of Perugia Medical School (Italy), In addition he has held Visiting Professors at AVP Hospital, Coimbatore (India) and S.D.M. College of Ayurveda, Udupi (India) where he taught postgraduate students, including in one of his specialism, lipid metabolism. He is an external supervisor for PhD students at Queen Mary University of London (QMUL). After graduating in Medical Sciences, he completed his Masters in Clinical Biochemistry and his PhD in the “Mechanism of Intake of Neurotransmitters” at the Sorbonne University (Paris). Following several years of medical and scientific research and published papers on the metabolism of cholesterol, he was awarded the Docteur d'Etat (Doctor of Science) in “Physiopathology of Nutrition by the Sorbonne, with the highest distinction (Très Honorable). Dr Cardona joined the WHRI in London under the Nobel laureate Sir John Vane, working with Professor Gustav Born on various aspects of Pathopharmacology. In parallel to his allopathic medical research and teaching, he has been studying and practicing integrative and Ayurvedic medicine for decades and holds a Masters in Ayurvedic Medicine from Middlesex University, UK, having completed internships at AVP Hospital Coimbatore and Udupi, India (2,000 hours+). He is a certified Ayurvedic Doctor by the National Ayurvedic Medical Association, USA (certified professional level) and has recently taught graduate students in Ayurveda at Bastyr University, Seattle and the University of New Mexico, NM. He is also a Member of the NHS Directory of Complementary & Alternative Practitioners, UK and presided for several years the Research Director of the Ayurvedic Professional Association (APA, UK). Dr. Cardona-Sanclemente is a Fellow of The Royal Society of Medicine (UK) and a Professional Member of the College of Medicine (UK). At present, he lives in Berkeley, CA and runs his private practice, and lectures nationally and internationally on Ayurveda, sharing his decades of experience at the interface of allopathic, integrative and Ayurvedic medical topics. He has delivered numerous engagements in building awareness and integration of the knowledge, efficacy and cost-effectiveness of Ayurveda and Integrative Medicine through developing health-related programs with academic, medical and non-profits organizations as part of his work for the integration and inclusion of minorities. Dr Cardona-Sanclemente has recently completed a book, due to be published in September 2020, on Ayurveda for Depression. He is fluent in English, Spanish, French and Italian. ​Website: https://www.eduardocardona.com/ Teri's #1 best-selling book and #1 new-release book can be found here.

Older Adult Podcast: 5 Forces Disrupting/Transforming Healthcare Today.  In todays episode, @Sam.c.dpt finishes discussing an older adult survey and study regarding health care of older adults with number 5. Advances in Medical Science, AI, and Health Care Delivery. Spoiler alert even with technology lifestyle behaviors such as adequate exercise, nutrient rich focused food intake, and social wellness are still the best option for a longer healthspan! https://podcasts.apple.com/us/podcast/discussing-the-5-forces-disrupting-transforming/id1050956449?i=1000675187357 https://podcasts.apple.com/us/podcast/5-forces-disrupting-transforming-healthcare-today-pt-2/id1050956449?i=1000689598273 https://podcasts.apple.com/us/podcast/5-forces-disrupting-transforming-healthcare-3-fragmentation/id1050956449?i=1000701045116 https://podcasts.apple.com/us/podcast/5-forces-disrupting-healthcare-workforce-shortage/id1050956449?i=1000708740281  

Founding director of the Doctor of Medical Science program at The College of St. Scholastica, Kenneth Botelho, discusses his article, "In the absence of physician mentorship, who will train the next generation of primary care clinicians?" Kenneth highlights the accelerating crisis caused by the erosion of physician mentorship, particularly impacting physician associates (PAs) in primary care who historically relied on close, hands-on guidance. He explains that with an aging physician workforce and doctors leaving primary care, this traditional apprenticeship model is breaking down, leaving many new PAs with minimal supervision and high-pressure roles, increasing risks of burnout and clinical error. Kenneth argues that while the old system cannot be revived, innovative solutions like postgraduate PA fellowships and residencies, supported by Doctor of Medical Science (DMSc) programs, offer a path forward. He details how these programs can create a new pipeline of PA leaders equipped with advanced clinical competence, leadership skills, and an understanding of value-based care and health care economics, enabling them to fill mentorship gaps and improve a strained health care system. Kenneth stresses that this is a system issue requiring bold, collaborative action to support learners and ensure patient safety. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Melanie Murphy Richter, MS, RDN is a highly recognized dietitian and nutritionist who holds the title of 2023 Recognized Young Dietitian of the Year by the Academy of Nutrition and Dietetics. She serves as the Director of Communication and Medical Science at El Nutra, where she is instrumental in promoting health through evidence-based nutrition. In addition to her role at El Nutra, Melanie is the founder of Holistic Ritual, which blends science-based nutrition with holistic healing. Her work has been featured in esteemed publications such as Forbes, USA Today, and Men's Health.Episode Summary:In this episode Melanie, a notable dietitian and Director at El Nutra, shares invaluable insights on how our dietary choices can significantly influence the aging process and quality of life. By focusing on plant-based diets while still acknowledging the benefits of some animal proteins, Melanie introduces the concept of 'plant-forward' eating as a sustainable and health-promoting approach.Melanie discusses the scientific underpinnings and health benefits of a plant-forward diet, not only for individual health but also as a practical approach within longevity hotspots around the world. She delves into the mechanisms of fasting mimicking diets (FMD), a cutting-edge area of nutritional science pioneered by Dr. Valter Longo, which can initiate autophagy—a critical process for cellular regeneration. Key Takeaways:Plant-Forward Nutrition: Impact of Fasting: Nutritional Balance: Health and Longevity: ShopifyShopify makes it simple to create your brand, open for business, and get your first sale. Go to Shopify.com/transformResources:Prolon Life: prolonlife.com - For products and more information on the fasting mimicking diet.El Nutra Health: lnutrahealth.com - For health programs related to metabolic conditions.To advertise on our podcast, visit https://advertising.libsyn.com/TransformyourMindor email kriti@youngandprofiting.com See this video on The Transform Your Mind YouTube Channel https://www.youtube.com/@MyhelpsUs/videosTo see a transcripts of this audio as well as links to all the advertisers on the show page https://myhelps.us/Follow Transform Your Mind on Instagram https://www.instagram.com/myrnamyoung/Follow Transform Your mind on Facebookhttps://www.facebook.com/profile.php?id=100063738390977Please leave a rating and review on iTunes https://podcasts.apple.com/us/podcast/transform-your-mind/id1144973094 https://podcast.feedspot.com/personal_development_podcasts/